EUVIMEDEUVIMED entdecken
CrossrefInfokarte

TNFR1 expression on cancer cells mediates immune escape and an immunosuppressive microenvironment

Elixabet Bolaños, Lorena Cañas-Zabala, Irene Olivera, David Ruiz Guillamón, Enric Vercher, Gabriel Gomis, Carlos E. de Andrea, Raluca Alexandru, Arantza Azpilikueta, Nekane Soria, Dayanna Salinas, Paula Molero-Glez, Carlos Luri-Rey, Saioa Arrieta-Aranzueque, Almudena Manzanal, Mario Garcia-Dominguez, Diego Alignani, Bruno Ségui, Angie Molina, Álvaro Teijeira, Pedro Berraondo, Ignacio Melero

Journal of Experimental Medicine · 2026-10-05 · 223 (10)

DOI: 10.1084/jem.20252080 ↗
AbstractBibliografische Angaben

Abstract

TNFα is a proinflammatory cytokine that can mediate immunosuppressive effects in cancer. Tumors in which we silenced TNFR1 by CRISPR/Cas9 showed that TNFR1KO variants poorly engrafted in immunocompetent hosts, while engraftment in immunodeficient or CD8 T lymphocyte–depleted mice was preserved. The mechanism was mediated by secondary chemotactic inflammatory mediators elicited by TNFα in the malignant cells themselves. As a result, TNFR1KO variants recruited drastically fewer myeloid-derived suppressor cells (MDSCs) into the tumor microenvironment, thus explaining the immune escape of the WT variants. Interestingly, small amounts of TNFR1-sufficient tumor cells co-engrafted with the TNFR1KO variants rescued tumorigenicity in the same tumor lesion but not in distantly implanted TNFR1KO tumors. Secondary mediators chiefly include CXCR1/2-acting chemokines, prostaglandin E2 and TNFα itself. Knocking down TNFR1 in a human tumor cell line rendered comparable MDSC-recruiting results when xenografted. Analyses of scRNA-seq and spatial transcriptomics datasets from human solid tumors corroborate the role of TNFR1 on tumor cells in the induction of secondary pro-tumor inflammatory mediators.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →